By comparing and contrasting exomes of diagnosis and relapse samples, we found that epigenetic modifiers, such as EP300, KMT2D, and SETDB1, were mutated in both diagnosis and relapse tumors, suggesting that these mutations could be the driver mutations of DLBCL. The gene discussed is SETDB1; the disease is diffuse large B-cell lymphoma.